Table 2.
Open in new tab

Multivariable Analysis: Chance of High Hematocrit for Different Determinants

Hematocrit > 0.50 L/L, crude OR (95% CI)Adjusted OR (95% CI)bHematocrit > 0.52 L/L, crude OR (95%CI)Adjusted OR (95% CI)b
Tobacco use2.2 (1.6–3.3)2.0 (1.3–3.0)3.2 (1.7–6.2)2.7 (1.3–5.5)
Positive medical historya2.5 (1.4–4.4)2.0(1.1–3.8)5.3 (2.3–12.3)4.6 (1.9–11.2)
Age at initiation
<18refrefrefref
18–302.5 (1.4–4.4)1.5(0.8–2.9)3.2 (1.0–9.9)1.9 (0.5–7.0)
30–403.9 (2.0–7.5)1.9 (0.9–4.0)5.7 (1.7–19.4)2.7 (0.6–11.3)
40–505.9 (2.8–12.3)3.1 (1.4–7.2)10.3 (2.8–38.8)4.9 (1.1–22.5)
≥502.6 (0.8–8.6)1.2 (0.3–4.5)2.9 (0.3–26.4)1.1 (0.1–13.5)
BMI
≤18.50.4 (0.2–1.2) 0.6 (0.2–1.9) n/a n/a
18.5–25refrefrefref
25–303.4 (2.1–5.5)3.0 (1.8–5.1)5.3 (2.3–12.3)4.3 (1.7–10.8)
≥303.7 (2.2–6.2)3.1 (1.7–5.6)6.1 (2.5–14.9)4.6 (1.7–12.3)
Route of testosterone
T gelrefrefrefref
Short-acting im1.1 (0.7–1.6)1.1 (0.7–1.7)1.5 (0.7–3.4)1.5 (0.6–3.7)
Long-acting im2.9 (1.7–5.0)3.1 (1.7–5.6)1.0 (0.3–3.4)1.3 (0.4–5.0)
Oral T0.6 (0.2–1.6)1.3 (0.4–3.7)0.2 (0.1–2.4)0.5 (0.1–5.6)
Unknown1.2 (0.8–1.7)1.9 (1.3–2.8)1.8 (0.9–3.8)2.9 (1.3–6.6)
Testosterone levels
0–10 nmol/L0.1 (0.1–0.2) 0.1 (0.1–0.2) 0.2 (0.1–0.4) 0.1 (0.1–0.4)
10–20 nmol/Lrefrefrefref
20–30 nmol/L1.3 (0.9–1.8)1.3 (0.9–1.8)1.3 (0.7–2.5)1.4 (0.7–2.7)
>30 nmol/L1.4 (1.0–1.9)1.5 (1.1–1.8)1.4 (0.7–2.5)1.6 (0.8–3.0)
Hematocrit > 0.50 L/L, crude OR (95% CI)Adjusted OR (95% CI)bHematocrit > 0.52 L/L, crude OR (95%CI)Adjusted OR (95% CI)b
Tobacco use2.2 (1.6–3.3)2.0 (1.3–3.0)3.2 (1.7–6.2)2.7 (1.3–5.5)
Positive medical historya2.5 (1.4–4.4)2.0(1.1–3.8)5.3 (2.3–12.3)4.6 (1.9–11.2)
Age at initiation
<18refrefrefref
18–302.5 (1.4–4.4)1.5(0.8–2.9)3.2 (1.0–9.9)1.9 (0.5–7.0)
30–403.9 (2.0–7.5)1.9 (0.9–4.0)5.7 (1.7–19.4)2.7 (0.6–11.3)
40–505.9 (2.8–12.3)3.1 (1.4–7.2)10.3 (2.8–38.8)4.9 (1.1–22.5)
≥502.6 (0.8–8.6)1.2 (0.3–4.5)2.9 (0.3–26.4)1.1 (0.1–13.5)
BMI
≤18.50.4 (0.2–1.2) 0.6 (0.2–1.9) n/a n/a
18.5–25refrefrefref
25–303.4 (2.1–5.5)3.0 (1.8–5.1)5.3 (2.3–12.3)4.3 (1.7–10.8)
≥303.7 (2.2–6.2)3.1 (1.7–5.6)6.1 (2.5–14.9)4.6 (1.7–12.3)
Route of testosterone
T gelrefrefrefref
Short-acting im1.1 (0.7–1.6)1.1 (0.7–1.7)1.5 (0.7–3.4)1.5 (0.6–3.7)
Long-acting im2.9 (1.7–5.0)3.1 (1.7–5.6)1.0 (0.3–3.4)1.3 (0.4–5.0)
Oral T0.6 (0.2–1.6)1.3 (0.4–3.7)0.2 (0.1–2.4)0.5 (0.1–5.6)
Unknown1.2 (0.8–1.7)1.9 (1.3–2.8)1.8 (0.9–3.8)2.9 (1.3–6.6)
Testosterone levels
0–10 nmol/L0.1 (0.1–0.2) 0.1 (0.1–0.2) 0.2 (0.1–0.4) 0.1 (0.1–0.4)
10–20 nmol/Lrefrefrefref
20–30 nmol/L1.3 (0.9–1.8)1.3 (0.9–1.8)1.3 (0.7–2.5)1.4 (0.7–2.7)
>30 nmol/L1.4 (1.0–1.9)1.5 (1.1–1.8)1.4 (0.7–2.5)1.6 (0.8–3.0)

Abbreviations: BMI, body mass index; im, intramuscular; n/a, no data available; OR, odds ratio; T, testosterone.

a Chronic obstructive pulmonary disease/asthma, sleep apnea, chronic bronchitis, polycythemia vera

b Adjusted for all other determinants

Table 2.
Open in new tab

Multivariable Analysis: Chance of High Hematocrit for Different Determinants

Hematocrit > 0.50 L/L, crude OR (95% CI)Adjusted OR (95% CI)bHematocrit > 0.52 L/L, crude OR (95%CI)Adjusted OR (95% CI)b
Tobacco use2.2 (1.6–3.3)2.0 (1.3–3.0)3.2 (1.7–6.2)2.7 (1.3–5.5)
Positive medical historya2.5 (1.4–4.4)2.0(1.1–3.8)5.3 (2.3–12.3)4.6 (1.9–11.2)
Age at initiation
<18refrefrefref
18–302.5 (1.4–4.4)1.5(0.8–2.9)3.2 (1.0–9.9)1.9 (0.5–7.0)
30–403.9 (2.0–7.5)1.9 (0.9–4.0)5.7 (1.7–19.4)2.7 (0.6–11.3)
40–505.9 (2.8–12.3)3.1 (1.4–7.2)10.3 (2.8–38.8)4.9 (1.1–22.5)
≥502.6 (0.8–8.6)1.2 (0.3–4.5)2.9 (0.3–26.4)1.1 (0.1–13.5)
BMI
≤18.50.4 (0.2–1.2) 0.6 (0.2–1.9) n/a n/a
18.5–25refrefrefref
25–303.4 (2.1–5.5)3.0 (1.8–5.1)5.3 (2.3–12.3)4.3 (1.7–10.8)
≥303.7 (2.2–6.2)3.1 (1.7–5.6)6.1 (2.5–14.9)4.6 (1.7–12.3)
Route of testosterone
T gelrefrefrefref
Short-acting im1.1 (0.7–1.6)1.1 (0.7–1.7)1.5 (0.7–3.4)1.5 (0.6–3.7)
Long-acting im2.9 (1.7–5.0)3.1 (1.7–5.6)1.0 (0.3–3.4)1.3 (0.4–5.0)
Oral T0.6 (0.2–1.6)1.3 (0.4–3.7)0.2 (0.1–2.4)0.5 (0.1–5.6)
Unknown1.2 (0.8–1.7)1.9 (1.3–2.8)1.8 (0.9–3.8)2.9 (1.3–6.6)
Testosterone levels
0–10 nmol/L0.1 (0.1–0.2) 0.1 (0.1–0.2) 0.2 (0.1–0.4) 0.1 (0.1–0.4)
10–20 nmol/Lrefrefrefref
20–30 nmol/L1.3 (0.9–1.8)1.3 (0.9–1.8)1.3 (0.7–2.5)1.4 (0.7–2.7)
>30 nmol/L1.4 (1.0–1.9)1.5 (1.1–1.8)1.4 (0.7–2.5)1.6 (0.8–3.0)
Hematocrit > 0.50 L/L, crude OR (95% CI)Adjusted OR (95% CI)bHematocrit > 0.52 L/L, crude OR (95%CI)Adjusted OR (95% CI)b
Tobacco use2.2 (1.6–3.3)2.0 (1.3–3.0)3.2 (1.7–6.2)2.7 (1.3–5.5)
Positive medical historya2.5 (1.4–4.4)2.0(1.1–3.8)5.3 (2.3–12.3)4.6 (1.9–11.2)
Age at initiation
<18refrefrefref
18–302.5 (1.4–4.4)1.5(0.8–2.9)3.2 (1.0–9.9)1.9 (0.5–7.0)
30–403.9 (2.0–7.5)1.9 (0.9–4.0)5.7 (1.7–19.4)2.7 (0.6–11.3)
40–505.9 (2.8–12.3)3.1 (1.4–7.2)10.3 (2.8–38.8)4.9 (1.1–22.5)
≥502.6 (0.8–8.6)1.2 (0.3–4.5)2.9 (0.3–26.4)1.1 (0.1–13.5)
BMI
≤18.50.4 (0.2–1.2) 0.6 (0.2–1.9) n/a n/a
18.5–25refrefrefref
25–303.4 (2.1–5.5)3.0 (1.8–5.1)5.3 (2.3–12.3)4.3 (1.7–10.8)
≥303.7 (2.2–6.2)3.1 (1.7–5.6)6.1 (2.5–14.9)4.6 (1.7–12.3)
Route of testosterone
T gelrefrefrefref
Short-acting im1.1 (0.7–1.6)1.1 (0.7–1.7)1.5 (0.7–3.4)1.5 (0.6–3.7)
Long-acting im2.9 (1.7–5.0)3.1 (1.7–5.6)1.0 (0.3–3.4)1.3 (0.4–5.0)
Oral T0.6 (0.2–1.6)1.3 (0.4–3.7)0.2 (0.1–2.4)0.5 (0.1–5.6)
Unknown1.2 (0.8–1.7)1.9 (1.3–2.8)1.8 (0.9–3.8)2.9 (1.3–6.6)
Testosterone levels
0–10 nmol/L0.1 (0.1–0.2) 0.1 (0.1–0.2) 0.2 (0.1–0.4) 0.1 (0.1–0.4)
10–20 nmol/Lrefrefrefref
20–30 nmol/L1.3 (0.9–1.8)1.3 (0.9–1.8)1.3 (0.7–2.5)1.4 (0.7–2.7)
>30 nmol/L1.4 (1.0–1.9)1.5 (1.1–1.8)1.4 (0.7–2.5)1.6 (0.8–3.0)

Abbreviations: BMI, body mass index; im, intramuscular; n/a, no data available; OR, odds ratio; T, testosterone.

a Chronic obstructive pulmonary disease/asthma, sleep apnea, chronic bronchitis, polycythemia vera

b Adjusted for all other determinants

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close